secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cardiff Oncology, Inc. (CRDF)
CIK:        0001213037
Form:       8-K
Filed at:   2022-02-24T23:59:59+00:00
Accession:  0001628280-22-003816
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cardiff Oncology reports Q4/FY2021 results; mCRC trial shows 34% ORR; Pfizer invests $15M
--------------------------------------------------------------------------------

- Onvansertib+FOLFIRI/bevacizumab in KRAS-mutated mCRC: 34% (12/35) ORR at RP2D; mPFS 9.4 months vs ~4.5-5.7 months historical control.
- Cash, equivalents, and short-term investments $141M as of Dec 31, 2021; Q4 operating expenses $9.6M (up from $6.6M in 2020).
- Pfizer invested $15M via equity purchase of 2.4M shares at $6.22 (19% premium); Pfizer executive to join Scientific Advisory Board.
- Appointed Tod Smeal as CSO (ex-Eli Lilly, Pfizer) and Charles Monahan as SVP Regulatory Affairs.
- Full year 2021 net cash used in operating activities $23.0M vs $16.3M in 2020.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1213037/000162828022003816/0001628280-22-003816-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1213037/000162828022003816/crdf-20220224.htm
  HTML page:      https://secwatch.observer/filing/0001628280-22-003816

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer